I make a donation

ADRIFT

Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation

2017

nombre de patients

nombre de centres participants

National multicentric trial

type de financement

Privé (Fonds de Dotation Action & Bayer)

Référence

NCT03273322

A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

ADRIFT conducted by Fonds de Dotation ACTION

Autres études

ARAMIS

En cours

Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.

EDUC-DAI

En cours

Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI